Epoprostenol en es it fr

Epoprostenol Brand names, Epoprostenol Analogs

Epoprostenol Brand Names Mixture

  • No information avaliable

Epoprostenol Chemical_Formula


Epoprostenol RX_link


Epoprostenol fda sheet

Epoprostenol FDA

Epoprostenol msds (material safety sheet)

Epoprostenol Synthesis Reference

No information avaliable

Epoprostenol Molecular Weight

352.465 g/mol

Epoprostenol Melting Point

No information avaliable

Epoprostenol H2O Solubility

No information avaliable

Epoprostenol State


Epoprostenol LogP


Epoprostenol Dosage Forms

Powder for solution

Epoprostenol Indication

For the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.

Epoprostenol Pharmacology

Epoprostenol has two major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. The effect of epoprostenol on heart rate in animals varies with dose. At low doses, there is vagally mediated brudycardia, but at higher doses, epoprostenol causes reflex tachycardia in response to direct vasodilation and hypotension. No major effects on cardiac conduction have been observed. Additional pharmacologic effects of epoprostenol in animals include bronchodilation, inhibition of gastric acid secretion, and decreased gastric emptying. No available chemical assay is sufficiently sensitive and specific to assess the in vivo human pharmacokinetics of epoprostenol.

Epoprostenol Absorption

No information avaliable

Epoprostenol side effects and Toxicity

Symptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of epoprostenol. Single intravenous doses at 10 and 50 mg/kg (2703 and 27,027 times the recommended acute phase human dose based on body surface area) were lethal to mice and rats, respectively. Symptoms of acute toxicity were hypoactivity, ataxia, loss of righting reflex, deep slow breathing, and hypothermia.

Epoprostenol Patient Information

Epoprostenol Organisms Affected

Humans and other mammals